Harrow Health (original) (raw)
Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company (Nasdaq: HROW) based in Nashville, TN. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx [sic], an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a 20millionSeriesAfinancing,andEtonisnowapubliclytradedcompany.In2017,HarrowstartedSurfacePharmaceuticals,hiringDr.KamranHosseinitobeitschiefexecutiveofficer.Surfacewasfundedwitha20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a 20millionSeriesAfinancing,andEtonisnowapubliclytradedcompany.In2017,HarrowstartedSurfacePharmaceuticals,hiringDr.KamranHosseinitobeitschiefexecutiveofficer.Surfacewasfundedwitha20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 Series A financing.
| Property | Value |
|---|---|
| dbo:abstract | Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company (Nasdaq: HROW) based in Nashville, TN. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx [sic], an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a 20millionSeriesAfinancing,andEtonisnowapubliclytradedcompany.In2017,HarrowstartedSurfacePharmaceuticals,hiringDr.KamranHosseinitobeitschiefexecutiveofficer.Surfacewasfundedwitha20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a 20millionSeriesAfinancing,andEtonisnowapubliclytradedcompany.In2017,HarrowstartedSurfacePharmaceuticals,hiringDr.KamranHosseinitobeitschiefexecutiveofficer.Surfacewasfundedwitha20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 Series A financing. In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its Chief Innovation Officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. (en) |
| dbo:formerName | Imprimis Pharmaceuticals ( - Jan 2019) (en) |
| dbo:foundingYear | 2012-01-01 (xsd:gYear) |
| dbo:industry | dbr:Pharmaceutical_Industry |
| dbo:keyPerson | dbr:Chief_executive_officer |
| dbo:numberOfLocations | 1 (xsd:nonNegativeInteger) |
| dbo:product | dbr:Pharmaceuticals |
| dbo:type | dbr:Public_company |
| dbo:wikiPageID | 48885625 (xsd:integer) |
| dbo:wikiPageLength | 15280 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1083098758 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Pyrimethamine dbr:Pharmaceutical_company dbr:United_States_Secretary_of_Veterans_Affairs dbr:Public_company dbc:Companies_listed_on_the_Nasdaq dbr:Compounding_pharmacy dbr:Chief_executive_officer dbr:Russell_Microcap_Index dbr:Ciclosporin dbr:Epipen dbr:Mylan dbr:The_Wall_Street_Journal dbr:Anthony_Principi dbr:Ledgewood,_New_Jersey dbr:Board_of_directors dbr:Compounding dbc:Companies_based_in_Nashville,_Tennessee dbr:Tiopronin dbr:Turing_Pharmaceuticals dbr:Allergan dbr:Drug_Enforcement_Administration dbr:Express_Scripts dbr:Federal_Food,_Drug,_and_Cosmetic_Act dbr:Formulary_(pharmacy) dbr:Oxford_Union dbr:Good_manufacturing_practice dbr:Pharmaceutical_formulation dbr:James_C._Greenwood dbc:Pharmaceutical_companies_of_the_United_States dbc:Health_care_companies_based_in_Tennessee dbr:Telehealth dbr:Martin_Shkreli dbr:Business_model dbr:Pharmaceutical_Industry dbr:Publicly_traded dbr:HIV_treatment dbr:Nashville,_Tennessee dbr:Eye_drop dbr:FDA_warning_letter dbr:Restasis dbr:Pharmaceuticals dbr:Leucovorin |
| dbp:bloomberg | HROW:US (en) |
| dbp:formerName | Imprimis Pharmaceuticals (en) |
| dbp:google | HROW (en) |
| dbp:hqLocationCity | Nashville, TN (en) |
| dbp:hqLocationCountry | United States (en) |
| dbp:industry | dbr:Pharmaceutical_Industry |
| dbp:keyPeople | (en) Andrew R. Boll (en) Mark L. Baum (en) |
| dbp:name | Harrow Health, Inc. (en) |
| dbp:numLocations | 1 (xsd:integer) |
| dbp:products | dbr:Pharmaceuticals |
| dbp:reuters | HROW.O (en) |
| dbp:secCik | 1360214 (xsd:integer) |
| dbp:subsid | (en) Eton Pharmaceuticals (en) ImprimisRx (en) Melt Pharmaceuticals (en) Surface Pharmaceuticals (en) Visionology.com (en) |
| dbp:symbol | HROW (en) |
| dbp:tradedAs | Russell Microcap Index component (en) NASDAQ:HROW (en) |
| dbp:type | dbr:Public_company |
| dbp:wikiPageUsesTemplate | dbt:Authority_control dbt:Infobox_company dbt:Official_website dbt:Reflist dbt:Sic dbt:Start_date_and_age dbt:Use_dmy_dates dbt:Finance_links dbt:Nashville_companies |
| dbp:yahoo | HROW (en) |
| dct:subject | dbc:Companies_listed_on_the_Nasdaq dbc:Companies_based_in_Nashville,_Tennessee dbc:Pharmaceutical_companies_of_the_United_States dbc:Health_care_companies_based_in_Tennessee |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment | Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company (Nasdaq: HROW) based in Nashville, TN. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx [sic], an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a 20millionSeriesAfinancing,andEtonisnowapubliclytradedcompany.In2017,HarrowstartedSurfacePharmaceuticals,hiringDr.KamranHosseinitobeitschiefexecutiveofficer.Surfacewasfundedwitha20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a 20millionSeriesAfinancing,andEtonisnowapubliclytradedcompany.In2017,HarrowstartedSurfacePharmaceuticals,hiringDr.KamranHosseinitobeitschiefexecutiveofficer.Surfacewasfundedwitha20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 Series A financing. (en) |
| rdfs:label | Harrow Health (en) |
| owl:sameAs | wikidata:Harrow Health https://global.dbpedia.org/id/25hxC |
| prov:wasDerivedFrom | wikipedia-en:Harrow_Health?oldid=1083098758&ns=0 |
| foaf:homepage | http://harrowinc.com |
| foaf:isPrimaryTopicOf | wikipedia-en:Harrow_Health |
| foaf:name | Harrow Health, Inc. (en) |
| is dbo:wikiPageRedirects of | dbr:Imprimis_Pharmaceuticals |
| is dbo:wikiPageWikiLink of | dbr:List_of_companies_based_in_Nashville,_Tennessee dbr:Imprimis_Pharmaceuticals dbr:Imprimis |
| is owl:differentFrom of | dbr:Imprimis |
| is foaf:primaryTopic of | wikipedia-en:Harrow_Health |